stockrow
Friday 6 November 2026
Export ROIV’s income statement to Excel — free account
Roivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
38.59
1.97
+5.38%
Follow ROIV
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3,386.66 | 2,354.61 | 1,136.13 | 506.80 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(94.30) | (118.72) | (76.96) | (55.49) | |
P/B ratio |
5.18 | 3.67 | 3.04 | 2.14 | |
Price to Tangible BV |
5.33 | 3.77 | 3.13 | 2.21 | |
EV/Sales |
2,919.53 | 1,874.21 | 820.11 | 306.98 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(26.93) | (20.63) | (14.38) | (8.11) | |
EV/FCF |
(26.78) | (20.41) | (14.23) | (7.96) | |
Quick Ratio |
16.27 | 18.00 | 29.81 | 32.77 | |
Current Ratio |
16.72 | 18.37 | 30.66 | 33.71 | |
Net Debt/EBITDA |
10.51 | (10.32) | 13.38 | 14.37 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.42 | (0.54) | 0.74 | 1.64 | |
Capex/Depreciation |
(0.70) | (1.98) | 7.14 | (8.52) | |
Research and Development Expense of Revenue |
14,009.43% | 7,894.64% | 8,273.14% | 10,475.37% | |
Selling, General and Administrative Expense of Revenue |
11,478.99% | 6,279.76% | 8,757.98% | 9,110.44% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5,779.61% | 3,062.26% | 5,252.48% | 5,208.21% | |
Graham Net Nets |
0.17 | 0.24 | 0.29 | 0.41 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.07%) | (1.62%) | (5.39%) | (3.70%) | |
Free Cash Flow Yield |
(3.22%) | (3.90%) | (5.07%) | (7.61%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.38) | (0.23) | (0.28) | (0.27) | |
Capex per Share |
0.00 | 0.00 | 0.01 | (0.01) | |
Free Cash Flow per Share |
(0.38) | (0.24) | (0.27) | (0.28) | |
Cash per Share |
5.33 | 6.11 | 6.50 | 6.44 | |
Shareholders Equity per Share |
6.83 | 7.54 | 7.14 | 7.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.83 | 7.54 | 7.14 | 7.06 | |
Free Cash Flow |
(270.92) | (165.08) | (191.55) | (193.51) | |
Working Capital |
4,458.48 | 4,886.14 | 4,507.93 | 4,377.79 | |
Capital Expenditures |
(0.42) | (1.26) | 4.94 | (7.85) | |
Net Current Asset Value |
4,357.46 | 4,751.11 | 4,408.75 | 4,254.51 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.29 | 0.50 | (2.47) | 5.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
18.32 | 20.85 | 18.50 | 20.10 | |
Average Assets |
5,169.55 | 5,572.81 | 5,508.86 | 5,634.31 | |
Average Common Equity |
4,868.89 | 5,239.81 | 5,255.10 | 5,192.75 |
Columns are period end dates · fundamentals updated 26 Oct 2026